Ashvattha Therapeutics announced that the first patient has been enrolled in a phase 1/2 study to evaluate the ability of an imaging agent to cross the blood-brain barrier and target key markers of neuroinflammation.
According to a company release, [18F]OP-801 is a hydroxyl dendrimer imaging agent that selectively targets reactive macrophages and microglia and may aid visualization of neuroinflammatory progression in diseases like ALS, Alzheimer’s disease and Parkinson’s disease.
The nonrandomized, open-label clinical trial, which is expected to enroll up to 26 individuals, will